Literature DB >> 10950757

Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection.

D M Koelle1, M Schomogyi, L Corey.   

Abstract

Genital reinfection with herpes simplex virus type 2 (HSV-2) is uncommon in humans. The mechanism of acquired immunity is unknown. Because the cervix is a site of HSV exposure, we measured antigen-specific T cell responses to HSV in cervical lymphocytes during both lesional and nonlesional time periods. Cells were expanded without secondary in vitro stimulation with antigen. Proliferative and cytotoxic responses to HSV were detectable in specimens from most subjects. Limiting dilution assays showed a high frequency of antigen-specific cells. Cytotoxic T cell responses included both CD4 and CD8 components. Responses were present both during and between symptomatic infection episodes and persisted during suppressive antiviral therapy. Natural infection with HSV-2 is associated with a persistent cervical mucosal cellular immune response. This local response may possibly assist in limiting the clinical consequences of secondary HSV-2 infection, whether due to endogenous reactivation or exogenous reinfection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950757     DOI: 10.1086/315749

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

Review 1.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 2.  The immunopathology of lung fibrosis: amphiregulin-producing pathogenic memory T helper-2 cells control the airway fibrotic responses by inducing eosinophils to secrete osteopontin.

Authors:  Kiyoshi Hirahara; Ami Aoki; Yuki Morimoto; Masahiro Kiuchi; Mikiko Okano; Toshinori Nakayama
Journal:  Semin Immunopathol       Date:  2019-04-09       Impact factor: 9.623

3.  Longitudinal analysis of herpes simplex virus-specific CD4+ cell clonotypes in infected tissues and blood.

Authors:  Serge Barcy; Meei-Li Huang; Lawrence Corey; David M Koelle
Journal:  J Infect Dis       Date:  2005-05-12       Impact factor: 5.226

4.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

5.  Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8+ TEM and TRM Cell Responses against Herpesvirus Infection and Disease.

Authors:  Patricia P Lopes; George Todorov; Thanh T Pham; Anthony B Nesburn; Elmostafa Bahraoui; Lbachir BenMohamed
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

6.  Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation.

Authors:  Abraham Guerrero; Stanley R Riddell; Jan Storek; Terry Stevens-Ayers; Barry Storer; John A Zaia; Stephen Forman; Robert S Negrin; Thomas Chauncey; William Bensinger; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-20       Impact factor: 5.742

7.  Immunomodulatory effects of HSV-2 infection on immature macaque dendritic cells modify innate and adaptive responses.

Authors:  Silvia Peretti; Andrew Shaw; James Blanchard; Rudolf Bohm; Gavin Morrow; Jeffrey D Lifson; Agegnehu Gettie; Melissa Pope
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

8.  Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.

Authors:  Francois-Xavier Mbopi-Kéou; Laurent Bélec; Julie Dalessio; Jérôme Legoff; Gérard Grésenguet; Philippe Mayaud; David W G Brown; Rhoda Ashley Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

9.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.

Authors:  X Zhang; A A Chentoufi; G Dasgupta; A B Nesburn; M Wu; X Zhu; D Carpenter; S L Wechsler; S You; L BenMohamed
Journal:  Mucosal Immunol       Date:  2008-12-24       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.